Cancer Research KI list of basic cancer research PIs across KI
Please find the basic science researchers within the cancer area at KI listed in the table below.
Note that this is an initial list that may still contain errors in part because the response rate on the conducted survey was below a hundred per cent. We would therefore like you to be in contact with us if you find that your name has been erroneously entered or if you would like to complete the current information in any way. Please send your update request to cancerresearchki@ki.se.
Contact details for the researchers can be found through the KI search function on the top right-hand side of this page.
Basic cancer research
| Surname | Given name | Department | Group website | Description |
|---|---|---|---|---|
| Andersson | Björn | CMB | https://ki.se/en/cmb/bjorn-anderssons-group | The use of virus metagenomics to study viruses in paediatric and other cancers. |
| Arnér | Elias | MBB | https://ki.se/en/mbb/elias-arner-research-group | Redox signaling, selenoproteins, thioredoxin system, glutathione peroxidases and biochemistry. Targeting of selenoproteins as anticancer therapy, triggering ferroptosis, transcription factor regulation, Nrf2 modulation and metabolic pathway switches. |
| Arvidsson | Per | MBB | ||
| Baranello | Laura | CMB | https://ki.se/en/cmb/laura-baranellos-group | We use biochemical and genomic approaches as well as drug screens to understand the mechanism of topoisomerases in transcription and how to target this mechanism to arrest cancer cell growth |
| Belkic | Dzevad | Onk-Pat | ||
| Bergö | Martin | BioNut | https://ki.se/en/bionut/cancer-rapid-ageing-and-nutrition-martin-bergo | Basic and translational cancer research on molecular mechanisms of tumor initiation, progression, and metastasis |
| Betsholtz | Christer | MedH | ||
| Bienko | Magda | MBB | ||
| Björkegren | Camilla | BioNut | https://ki.se/en/cmb/camilla-bjorkegrens-group | Basic medically relevant research on chromosome stability and dynamics. In vivo and in vitro. |
| Björkhem | Ingemar | LabMed | ||
| Björnstedt | Mikael | LabMed | ||
| Blomqvist | Lennart | MMK | ||
| Cao | Yihai | MTC | ||
| Crosetto | Nicola | MBB | https://ki.se/en/mbb/nicola-crosetto-group | Development of novel sequencing approaches for profiling tumor heterogeneity and studying genome fragility and structure in cancer. 1) Cancer genomics; 2) Genome instability and 3D genome organization in cancer |
| Dantuma | Nico | CMB | https://ki.se/en/cmb/nico-dantumas-group | Exploring intracellular protein degradation, in particular the ubiquitin-proteasome system, as therapeutic target. |
| Díaz De Ståhl | Teresita | Onk-Pat | ||
| Dreij | Kristian | IMM | ||
| Einhorn | Stefan | Onk-Pat | ||
| Ekwall | Karl | BioNut | ||
| Elsässer | Simon | MBB | https://elsaesserlab.wordpress.com | Cancer epigenomics, oncogenic histone mutants,G4 structures, ssDNA and SSB mapping |
| Enge | Martin | Onk-Pat | https://ki.se/en/onkpat/research-team-martin-enge | Single-cell genomics of cancer, with a focus on childhood leukemia and pancreatic cancer. |
| Eriksson | Maria | Bionut | ||
| Espinosa | Alexander | MedS | ||
| Fadeel | Bengt | IMM | ||
| Farnebo | Marianne | Bionut | ||
| Fernandez-Capetillo | Oscar | MBB | https://ki.se/en/mbb/oscar-fernandez-capetillo-group | I try to combine mouse models, cell biology and genetic and chemical screens for developing new therapies. |
| Gabrielsson | Susanne | MedS | The role of cancer-derived exosomes in disease and how to use exosomes for therapy. | |
| Genové | Guillem | MedH | To understand the role of pericytes in tumors and their role in immune cell recruitment | |
| Girnita | Leonard | Onk-Pat | ||
| Göndör | Anita | Onk-Pat | ||
| Grafström | Roland | IMM | ||
| Gustafsson | Nina | Onk-Pat | https://ki.se/en/onkpat/research-team-nina-gustafsson | Our research is focused on understanding how altered metabolism can regulate the DNA repair capacity of cancer cells with the goal to translate our findings into novel treatments for cancer patients. |
| Hausser | Jean | CMB | https://ki.se/en/cmb/jean-haussers-group | We research quantitative rules in tumor biology. We aim to formulate these rules in the form of equations that state how key tumor properties relate to each other: cellular composition of the tumor, functional heterogeneity among cells found in the tumor, spatial organization, tumor growth rate, tumor size, shedding rate of metastatic cells, and so on. Finding mathematical order in the complexity of the tumor micro-environment could support diagnostics, prognosis and inform the design of immunotherapy in the future. It could also enhance ongoing efforts to apply artificial intelligence and machine-learning techniques to cancer. |
| Helleday | Thomas | Onk-Pat | Basic research into DNA damage response and repair and translating to novel treatments and clinical trials. | |
| Högberg | Johan | IMM | ||
| Högberg | Björn | MBB | ||
| Holmgren | Lars | Onk-Pat | ||
| Höög | Christer | CMB | Segregation of chromosomes at the metaphase/anaphase stage of the cell cycle during mitosis and meiosis. | |
| Jacobsson | Hans | MMK | ||
| Jakobsson | Per-Johan | MedS | https://ki.se/en/meds/research-group-per-johan-jakobsson | Role of prostaglandin E2 and microsomal prostaglandin E synthase inhibition in cancer |
| Jakobsson | Lars | MBB | https://ki.se/en/mbb/lars-jakobsson-group | Blood vessels in the context of tumour biology. Angiogenesis, fibrosis, and matrix biology in genetic mouse models. |
| Johnson | Randall | CMB | Hypoxia and its role in tumor pathology and immunotherapy | |
| Kutter | Claudia | MTC | https://ki.se/en/mtc/claudia-kutter-group | We investigate how gene regulation and transcriptional complexity contributes to cancerogenesis. We are particularly interested in dissecting the roles of non-coding and coding RNAs interact by using and developing -omics approaches, CRISPR technology and phenotypical screening. |
| Lain | Sonia | MTC | https://ki.se/en/mtc/sonia-lain-group | Cancer drug discovery: from phenotypic screens to the identification of the mechanism of action for small molecules. |
| Landreh | Michael | MTC | ||
| Lane | David | MTC | ||
| Larsson | Ola | Onk-Pat | https://ki.se/en/onkpat/ola-larssons-group | Studies of how mRNA translation is dysregulated in cancer. Identification of potential avenues for treatment by targeting dysregulated mRNA translation. |
| Larsson | Olle | Onk-Pat | ||
| Larsson | Nils-Göran | MBB | We work on the development of drugs for cancer treatment by inhibiting mitochondrial transcription and translation. | |
| Larsson | Lars-Gunnar | MTC | ||
| Lehti | Kaisa | MTC | ||
| Lehtiö | Janne | Onk-Pat | https://ki.se/en/onkpat/janne-lehtios-group | Proteomics and multi-omics driven cancer research with focus on lung and breast cancer as well as leukemia. Experimental cancer systems biology and predictive biomarker research. |
| Lemmens | Bennie | MBB | https://ki.se/en/mbb/bennie-lemmens-group | The Lemmens laboratory tries to understand how dividing cells maintain genome stability and based on that knowledge find innovative ways to tackle cancer and drug resistance. We develop time-resolved genetics and cutting-edge imaging technologies to determine how human cells maintain, copy and propagate DNA. |
| Lindqvist | Arne | CMB | ||
| Linnarsson | Sten | MBB | ||
| McInerney | Gerald | MTC | ||
| Menendez Benito | Victoria | BioNut | ||
| Morgenstern | Ralf | IMM | ||
| Nilsson | Roland | MedS | https://ki.se/en/meds/research-group-roland-nilsson | My group studies cancer metabolism, particularly one-carbon and methionine metabolism, striving to identify new drug targets. We use large-scale metabolomics techniques and stable isotope tracing to measure metabolism. |
| Norberg | Helin | FyFa | Our ultimate goal is to understanding how pathogenic proteins can be eliminated by degradation pathways in cancer cells. In particular our research focuses on oncogenic targeting. | |
| Nordenskjöld | Magnus | MMK | ||
| Nordlund | Pär | Onk-Pat | ||
| Ohlsson | Rolf | Onk-Pat | ||
| Page | Brent | Onk-Pat | We use state of the art chemical biology and medicinal chemistry techniques to identify novel cancer therapeutic agents. | |
| Panaretakis | Theocharis | IMM | ||
| Patarroyo | Manuel | MTC | Decoding the molecular basis of tumor aggressiveness (tumor growth, invasion, metastasis and chemoresistance) to develop novel therapeutic strategies | |
| Pawitan | Yudi | MEB | ||
| Pelechano Garcia | Vicente | MTC | https://ki.se/en/mtc/vicente-pelechano-group | We work on the fundamental aspects of gene expression controlling cell-to-cell variability in cancer, with a focus on Epigenetics, transcription and ribosome dynamics. |
| Pereira | Teresa | MMK | ||
| Petzold | Katja | MBB | http://petzoldlab.com/ | We work on RNA biophysics and structural biology, with focus on microRNA, ribosomes, viral RNA & drug development |
| Pietrocola | Federico | BioNut | ||
| Rannug | Agneta | IMM | ||
| Riedel | Christian | BioNut | https://ki.se/en/bionut/ageing-basic-mechanisms-and-interventions-chris… | We are interested in a) aneuploidy (one of the hallmarks of cancer) and b) the communication between cancer cells and their surroundings. |
| Rolny | Charlotte | Onk-Pat | https://ki.se/en/onkpat/charlotte-rolnys-group | We are studying the underlying mechanisms that regulate macrophages immunosuppressive and prometastatic functions. |
| Rudd | Sean | Onk-Pat | https://ki.se/en/onkpat/research-team-sean-rudd | The Rudd lab investigates metabolic pathways operating inside cancer cells and how these pathways support malignant disease. We are particularly focused upon the metabolic interplay between the DNA precursor pool and the DNA molecule, a relationship that is fundamental to cancer biology, underpinning key aspects of oncogenesis together with therapy resistance. |
| Sandberg | Rickard | CMB | ||
| Schlisio | Susanne | MTC | https://ki.se/en/mtc/susanne-schlisio-group | cancer arising from the sympathoadrenal lineage, such as neuroblastoma and pheochromocytoma |
| Schüler | Herwig | BioNut | https://ki.se/en/bionut/protein-adp-ribosylation-herwig-schuler | Pre-clinical development of PARP inhibitors |
| Schulte | Gunnar | FYFA | https://ki.se/en/fyfa/schulte-lab | Molecular understanding of WNT and Frizzled signaling with special emphasis on drug discovery for anticancer therapy targeting Frizzleds. |
| Selivanova | Galina | MTC | https://ki.se/en/mtc/galina-selivanova-group | p53 biology, small molecules restoring p53, anti-cancer therapy |
| Strang | Peter | Onk-Pat | ||
| Ström | Lena | CMB | https://ki.se/en/cmb/lena-stroms-group | Importance of chromosome organization and DNA repair for genome integrity. |
| Strömblad | Staffan | BioNut | https://ki.se/en/bionut/cell-biology-of-cancer-staffan-stromblad-0 | Role of Cell-matrix interactions andCellular signaling in Cancer |
| Svensson | Peter | BioNut | https://ki.se/en/bionut/mechanisms-behind-hiv-1-latency-and-rebound-pet… | Mechanistic insights into the (mis)regulation of transcription and chromatin |
| Szekely | Laszlo | LabMed | High throughput drug sensitivity measurement of primary human tumors | |
| Taipale | Jussi | MBB | ||
| Teixeira | Ana | MBB | We investigate how the organisation of membrane proteins at the nanoscale affects their functions in normal and cancer cells. | |
| Tham | Emma | MMK | https://ki.se/en/mmk/clinical-genetics | "Hereditary cancer syndromes - genetic causes and phenotypic characterisationCell-free tumour DNA as a biomarker for diagnosis, prognosis and monitoring of cancer" |
| Treuter | Eckardt | BioNut | ||
| Uhlén | Per | MBB | http://www.uhlenlab.org | Our group studies the intratumoral heterogeneity in various types of human cancer. We explore cancer stem cells, cell niches, and the tumor vasculature in intact tumor samples. |
| Walfridsson | Julian | MedH | ||
| Warpman Berglund | Ulrika | onk-Pat | The research aims to i) purifying and targeting proteins in DNA repair and metabolism, ii) use probes and genetic tools to increase basic knowledge around target proteins and iii) translating basic research findings into new treatments tested in clinic | |
| Wedell | Anna | MMK | ||
| Wiman | Klas | Onk-Pat | https://ki.se/en/onkpat/klas-g-wimans-group | Tumor biology, tumor suppressor genes, p53, cell death, cancer drug discovery, APR-246, clinical trials |
| Xu | Dawei | MedS | ||
| Zinzalla | Giovanna | MTC | https://staff.ki.se/people/giozin | Targeting two masters of transcriptional regulation: the MYC family of transcriptions and the SWI/SNF (BAF) chromatin remodelling complexes using biochemistry, biophysics and structural biology to determine key protein-protein interactions, and chemistry methods to develop new synthetic agents as potential therapeutics. |
| Zubarev | Roman | MBB | http://ki.se/en/mbb/roman-zubarev-group | Chemical proteomics of cancer cells and cancer stem cells |
| Åkesson | Agneta | IMM | https://ki.se/en/imm/unit-of-cardiovascular-and-nutritional-epidemiology | Diet and environmental contaminants and risk of cancer target this mechanism to arrest cancer cell growth |
| Östling | Päivi | Onk-Pat | Precision cancer medicine. We are linking spatial tissue maps to drug profiles for patient stratification and treatment prediction. | |
| Östman | Arne | Onk-Pat | https://ki.se/en/onkpat/arne-ostmans-group | Translational studies on tumor microenvironment with focus on cancer-associated fibroblasts |